Semaglutide vs Liraglutide

community guides:

related topics:

Community Q&A

What is the difference between semaglutide and liraglutide?

Both are GLP-1 receptor agonists used for weight loss and type 2 diabetes, but community accounts describe the practical differences as substantial. Liraglutide (Victoza, Saxenda) is a first-generation GLP-1 with a half-life of about 13 hours — requiring daily injection. Semaglutide is a second-generation GLP-1 engineered for a half-life of approximately 7 days — weekly dosing. Beyond dosing frequency, accounts that have used both describe semaglutide as producing significantly stronger appetite suppression and greater weight loss at their respective standard doses. The community framing: liraglutide was the category-defining GLP-1 before semaglutide; accounts of new users starting GLP-1 therapy after 2021 describe beginning with semaglutide rather than liraglutide in nearly all cases.

Is semaglutide more effective than liraglutide for weight loss?

Community accounts give semaglutide a consistent and clear advantage for weight loss. Accounts from users who transitioned from liraglutide to semaglutide describe markedly stronger appetite suppression and faster weight loss on semaglutide. Research-aware accounts cite the clinical data: semaglutide at 2.4mg weekly produces roughly 15–17% body weight loss in trials; liraglutide at 3mg daily produces roughly 5–8%. Community accounts describe outcomes broadly aligned with this — semaglutide accounts describe more dramatic results with stronger appetite attenuation. The only context where liraglutide is still preferred in community accounts: users who need a shorter half-life due to side effect management, or those with cost or access constraints.

Which has fewer side effects — semaglutide or liraglutide?

Community accounts don't produce a clear winner on tolerability. Liraglutide's shorter half-life is cited in accounts as producing milder but more frequent GI disturbance — nausea that comes and goes with each daily dose rather than persisting through the week. Semaglutide accounts describe fewer total instances of nausea once adapted, but when nausea occurs from a weekly dose, it can persist for days rather than hours. Accounts switching from liraglutide to semaglutide describe a tolerability adjustment period — most describe full adaptation within 4–8 weeks. Injection site reactions appear slightly more in liraglutide accounts, attributed to daily rotation requirements versus weekly for semaglutide.

Why did people switch from liraglutide to semaglutide?

The switch accounts in community data cite three consistent reasons. First, efficacy — accounts describe substantially more weight loss on semaglutide for the same or less effort. Second, dosing convenience — weekly versus daily injection is described as a meaningful quality-of-life improvement in virtually all switch accounts. Third, market availability — as compounded semaglutide became accessible, the cost differential that had previously favoured liraglutide narrowed or reversed. Accounts that remained on liraglutide after semaglutide became available describe specific reasons: established stable protocol with good results, particular tolerance to liraglutide's side effect pattern, or clinical prescription predating semaglutide's availability.